EC Number   |
Application |
Reference |
|---|
   3.5.2.6 | diagnostics |
diagnostic utility of the combination of Syn 2190 and cefotetan in a disk test for the detection of clinical isolates of Klebsiella sp. producing plasmid-mediated AmpC beta-lactamases. The sensitivity of this test is 91%, the specificity is 100%, and the reproducibility is 100% |
665831 |
| 3.5.2.6 | drug development |
enzyme BlaC is a rational enzyme target for therapeutic agents in treatment of tuberculosis caused by Mycobacterium tuberculosis |
-, 756194 |
| 3.5.2.6 | drug development |
the enzyme is a target for treatment of Mycobacterium abscessus infections |
-, 734040 |
| 3.5.2.6 | drug development |
the PWP triad is an evolutionarily conserved motif unique to class A beta-lactamases aligning its allosteric site and hence is an effective potential target for enzyme regulation and selective drug design |
757320 |
| 3.5.2.6 | drug development |
ZINC01807204 might be useful as a lead molecule for further optimization and development of more potent non beta-lactam inhibitors against KPC-2 |
-, 735123 |
| 3.5.2.6 | medicine |
beta-lactamases, which catalyze the inactivation of beta-lactam antibiotics such as penicillins and cephalosporins are of great interest because of their high incidence in pathogenic bacteria |
695375 |
| 3.5.2.6 | medicine |
putative development of a screening of MBL producing strains by routine clinical microbiology laboratories. The detection of the MBL phenotype of resistance is of crucial importance for selecting the most appropriate therapy and applying infection control measures |
693359 |
| 3.5.2.6 | medicine |
putative development of a screening of MBL producing strains by routine clinical microbiology laboratories. The detection of the MBL phenotype of resistance is of crucial importance for selecting the most appropriate therapy and applying infection control measures. |
693359 |
| 3.5.2.6 | medicine |
putative development of a screening of MBL producing strains by routine clinical microbiology laborities. The detection of the MBL phenotype of resistance is of crucial importance for selecting the most appropriate therapy and applying infection control measures |
693359 |
| 3.5.2.6 | pharmacology |
enzyme is a target for design of non-beta-lactam, broad-spectrum peptidomimetic enzyme inhibitors |
657231 |
